US 12,268,787 B2
Composition for use in the treatment of urinary or faecal incontinence
Jani Kuula, Espoo (FI); Eija Raussi-Lehto, Espoo (FI); Orlando Rojas, Espoo (FI); Rubina Ajdary, Espoo (FI); and Tomi Mikkola, Espoo (FI)
Assigned to Lignum Medical Oy, Helsinki (FI)
Appl. No. 18/282,545
Filed by Lignum Medical Oy, Helsinki (FI)
PCT Filed Jan. 28, 2022, PCT No. PCT/FI2022/050054
§ 371(c)(1), (2) Date Sep. 18, 2023,
PCT Pub. No. WO2022/195158, PCT Pub. Date Sep. 22, 2022.
Claims priority of application No. 20217052 (FI), filed on Mar. 16, 2021.
Prior Publication US 2024/0165046 A1, May 23, 2024
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 31/717 (2006.01); A61L 27/20 (2006.01); A61L 27/54 (2006.01)
CPC A61K 9/70 (2013.01) [A61K 9/0024 (2013.01); A61K 31/717 (2013.01); A61L 27/20 (2013.01); A61L 27/54 (2013.01); A61L 2300/412 (2013.01); A61L 2300/64 (2013.01); A61L 2400/06 (2013.01); A61L 2400/12 (2013.01); A61L 2430/22 (2013.01); A61L 2430/34 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A composition for use as a bulking agent, which is configured to be injected inside a wall of the urethra of a mammal or inside a wall of the rectum of a mammal, in the treatment of urinary or faecal incontinence respectively, the composition comprising a nanostructured cellulosic material,
wherein the composition comprises 0.5 to 5.0 wt-% of the nanostructured cellulosic material and at least 95 wt-% water,
wherein the nanostructured cellulosic material comprises never-dried nanostructured cellulosic material which has been manufactured by a pulping process,
wherein the nanostructured cellulosic material comprises cellulosic fibres having a length-to-width aspect ratio of at least 500.